文献速递肿瘤 PET/CT

癌症患者接种BNT162b2 mRNA新冠疫苗后腋窝淋巴结高代谢的队列研究

Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study.
PubMed 文献 · Clin Nucl Med · 2021-01-01

该回顾性队列研究纳入650例近期接种BNT162b2 mRNA新冠疫苗的癌症患者,分析FDG PET/CT上高代谢腋窝淋巴结(HAL)的发生与模式。结果显示,第1剂后HAL发生率为14.5%,第2剂后为43.3%(P<0.0001),两剂间SUVmax、SUVmean、反应性体积及淋巴结数目与大小均无显著差异。结论认为,mRNA疫苗接种后同侧小腋窝淋巴结簇状高代谢常见,主要见于第2剂后。

要点

  • 第2剂后HAL发生率43.3%,显著高于第1剂的14.5%(P<0.0001)。
  • 两剂间SUVmax、SUVmean、反应性体积及淋巴结数目与大小均无显著差异。
  • 接种后同侧小腋窝淋巴结簇状高代谢常见,主要见于第2剂后。

核心结论

  • mRNA新冠疫苗接种后同侧小腋窝淋巴结簇状高代谢常见,主要见于第2剂后。

研究设计与样本

  • 单中心回顾性队列研究,纳入650例近期接种BNT162b2 mRNA新冠疫苗的连续癌症患者,分析FDG PET/CT上HAL的发生与模式。

主要发现

  • 第1剂后12.3±5.9(1-22)天,394例中57例(14.5%,95%CI 10.9%-18.7%)出现HAL。
  • 第2剂后7.5±5.4(1-22)天,256例中111例(43.3%,95%CI 35.3%-52.2%)出现HAL,与第1剂比较P<0.0001。
  • 第1剂与第2剂后SUVmax分别为3.7±1.8(1.3-11.3)与4.5±3.9(1.4-26.3),P=0.13。
  • 第1剂与第2剂后SUVmean分别为2.1±1.0(0.7-6.5)与2.7±2.4(0.8-17),P=0.08。
  • 第1剂与第2剂后反应性体积分别为2.7±2.3(0.2-11.6)cm3与2.7±2.4(0.2-15.5)cm3,P=0.98。

关键数值与推荐

  • 第1剂与第2剂后阳性淋巴结数目分别为3.2±2.2(1-10)与3.7±2.4(1-12),P=0.18。
  • 第1剂与第2剂后阳性淋巴结大小分别为1.4±0.4 cm(0.7-2.5 cm)与1.5±0.4 cm(0.6-3.2 cm),P=0.75。

临床怎么用

  • 癌症患者FDG PET/CT见同侧小腋窝淋巴结簇状高代谢时,应结合近期mRNA新冠疫苗接种史,避免不必要的焦虑、进一步检查或昂贵活检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recognition of the pattern of FDG uptake in hypermetabolic axillary lymph nodes (HALs) and association with recent messenger RNA (mRNA) vaccination are important to prevent patient anxiety and further needless examinations or costly biopsies in cancer patients. MATERIALS AND METHODS: This study was a retrospective cohort study in a single tertiary care institution. We investigate the occurrence and pattern of HAL on FDG PET/CT scans from 650 consecutive cancer patients with recent BNT162b2 mRNA COVID-19 vaccination. RESULTS: Between December 20, 2020, and February 8, 2021, 650 patients (351 female patients [54%]; mean age, 68.9 years) had recent mRNA COVID-19 vaccination and an FDG PET/CT scan. HALs were found in 57 (14.5%) of 394 patients (95% confidence interval [CI], 10.9%-18.7%) 12.3 ± 5.9 (1-22) days after dose 1 and in 111 (43.3%) of 256 patients (95% CI, 35.3%-52.2%; P < 0.0001) after 7.5 ± 5.4 (1-22) days after dose 2. There was no difference between dose 1 and dose 2 concerning SUVmax (3.7 ± 1.8 [1.3-11.3] and 4.5 ± 3.9 [1.4-26.3], P = 0.13, respectively), SUVmean (2.1 ± 1.0 [0.7-6.5] and 2.7 ± 2.4 [0.8-17], P = 0.08, respectively), and reactogenicity volume (2.7 ± 2.3 [0.2-11.6] cm3 and 2.7 ± 2.4 [0.2-15.5] cm3, P = 0.98, respectively). There was no difference in number and in size of positive lymph nodes between dose 1 and dose 2: 3.2 ± 2.2 (1-10) and 3.7 ± 2.4 (1-12) (P = 0.18), and 1.4 ± 0.4 cm (0.7-2.5 cm) and 1.5 ± 0.4 cm (0.6-3.2 cm) (P = 0.75), respectively. CONCLUSIONS: A cluster pattern of hypermetabolic ipsilateral small axillary lymph nodes is common after mRNA COVID-19 vaccination, mainly after the second injection.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bernstine H, Priss M, Anati T, et al. Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study. Clin Nucl Med. 2021. PMID: 33782299. doi:10.1097/RLU.0000000000003648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。